PBMEF Indicators

Are you on a successful path to ending tuberculosis (TB)? This group of indicators will help you answer that question by providing standardized comparisons across the United States Agency for International Development’s (USAID’s) TB priority countries. These indicators are intended to help measure each outcome and impact; help decision-makers answer questions; and measure progress towards global and individual country targets.

Contains example visualizations with real data.

Core Indicators

Reach

[RN-1] Drug-Resistant TB Notifications

[CI-1] Contact Investigation Coverage

[DT-3] TB Case Detection Rate or TB Treatment Coverage

[DT-12] Bacteriological Diagnosis Coverage (Pulmonary TB)

[CH-5] Childhood TB Notifications

[PR-1] Private Sector TB Notifications

Cure

[RS-1] Drug-Resistant TB Treatment Success Rate (TSR)

[SS-1] TB Treatment Success Rate (TSR)

Prevent

[PT-1] Number of Individuals Started on TB Preventive Treatment (TPT)

Sustain

[SN-1] Percent of TB Financing Expected from Domestic Sources

Extended Indicators

Active Case Finding (AF)

[AF-7] Number Needed to Screen to Find One TB Case

[AF-8] Number Needed to Test to Find One TB Case

[AF-1] Number of Individuals Eligible for Screening

[AF-2] Number of Individuals Screened for TB

[AF-4] Number of Presumptive TB Cases Identified

[AF-5] Number of Presumptive TB Cases Tested for TB

[AF-6] Number of Presumptive TB Cases with Confirmed TB

[AF-9] Number with Confirmed TB Starting Appropriate Treatment

[AF-3] Screening Coverage among Risk Groups

Show More Show Less

Childhood TB (CH)

[CH-13] Childhood (Ages 0-14) DR-TB Notifications

[CH-23] Childhood DR-TB (Ages 0-14) Treatment Outcome: Died

[CH-22] Childhood DR-TB (Ages 0-14) Treatment Success Rate

[CH-26] Childhood DR-TB Treatment Outcome: Not Evaluated

[CH-8] Childhood TB (0-4) Notifications

[CH-9] Childhood TB (5-14) Notifications

[CH-7] Childhood TB Detection

[CH-3] Children (0-14 years) Clinically Evaluated for TB

[CH-1] Estimated Number of TB Cases among 0-14-year-old Children

[CH-2] Estimated Number of TB Deaths among 0-to-14-year-old Children

[CH-21] Number of Childhood DR-TB (Ages 0-14) Who Were Enrolled on Appropriate DR-TB Treatment by Regimen during a Specified Period

[CH-12] Percent of Notified New and Relapse Extrapulmonary TB Notifications (0-14 years-old) with Bacteriological Confirmation

[CH-11] Percent of Notified New and Relapse Pulmonary TB Notifications (0-14 years-old) with Bacteriological Confirmation

[CH-6] Percentage of New and Relapse TB Case Notifications That Are among 0-14-year-old Children, Calculated at National and Subnational Level

[CH-10] Ratio of 0-4 to 5-14 years-old Notifications

[CH-29] Stockouts of Child-friendly Formulations for TB Treatment, by Year and Length of Stockout

[CH-17] Treatment Outcome for Childhood TB (Ages 0-14): Died

[CH-19] Treatment Outcome for Childhood TB (Ages 0-14): Lost to Follow-up (LTFU)

[CH-20] Treatment Outcome for Childhood TB (Ages 0-14): Not Evaluated

[CH-18] Treatment Outcome for Childhood TB (Ages 0-14): Treatment Failed

[CH-14] Treatment Success Rate for Childhood TB (Ages 0-14)

[CH-15] Treatment Success Rate for Childhood TB (Ages 0-4)

[CH-16] Treatment Success Rate for Childhood TB (Ages 5-14)

[CH-27] Use of Child-friendly Formulations for TB Treatment, First-line Drugs (Yes/No)

[CH-28] Use of Child-friendly Formulations for TB Treatment, Second-line Drugs (Yes/No)

Show More Show Less

Contact Investigation (CI)

[CI-12] Contacts Screened Negative for TB

[CI-2] Estimated Average Number of Household Contacts Identified per One Notified New and Relapse Bacteriologically Confirmed Pulmonary TB Case

[CI-7] Percent of Close Contacts who Tested Positive for TBI

[CI-5] Percent of Contacts Detected with DR-TB Disease through Contact Investigation of DR-TB Index Case

[CI-6] Percent of Contacts Detected with DS-TB Disease through Contact Investigation of DR-TB Index Case

[CI-4] Percent of Contacts Detected with TB Disease

[CI-11] Percent of Contacts Diagnosed with TB Disease and Started on Treatment

[CI-3] Percent of Contacts Evaluated for TB Disease

[CI-8] Percent of Eligible Index Cases with Contact Investigations Conducted

[CI-9] Percent of Identified Contacts Investigated

[CI-10] Percent of Referred Contacts who Completed Evaluation

Show More Show Less

Drug-Resistant TB Notifications (RN)

[RN-2] DR-TB Case Detection

[RN-5] DR-TB Treatment Enrollment Coverage

[RN-4] Number of DR-TB Enrolled on Treatment

[RN-8] Number of DR-TB initiated on "all oral" longer treatment regimen

[RN-7] Number of DR-TB initiated on "all oral" short treatment regimen

[RN-6] Number of Treatment Sites Providing DR-TB Treatment

Drug-Resistant TB Treatment Success (RS)

[RS-2] DR-TB Treatment Outcome: Died

[RS-4] DR-TB Treatment Outcome: LTFU

[RS-3] DR-TB Treatment Outcome: Treatment failed

[RS-5] Drug-resistant TB Treatment Outcome: Not evaluated

[RS-6] Number of Patients on DR-TB Treatment Who Had Adverse Events Registered in the Reporting Year

[RS-7] Percent of DR-TB Patients Who Receive DR-TB Care Package

Healthcare Worker Screening (HW)

[HW-9] Contacts: HCWs Who Were Ruled Out for TB Disease, and Are Eligible Household Contacts

[HW-10] Contacts: HCWs Who Were Ruled Out for TB Disease, Are Eligible Household Contacts, and Were Initiated on TPT

[HW-13] HCWs Who Completed TPT

[HW-4] HCWs Who Were Ruled Out for TB Disease

[HW-3] Percentage of HCWs Diagnosed with TB Disease

[HW-1] Percentage of HCWs Screened for TB

[HW-2] Percentage of HCWs Screened Positive for TB

[HW-5] Percentage of HCWs Tested for TBI

[HW-6] Percentage of HCWs Tested Positive for TBI among HCWs

[HW-7] PLHIV: HCWs Who Were Ruled Out for TB Disease, and are PLHIV

[HW-8] PLHIV: HCWs Who Were Ruled Out for TB Disease, are PLHIV, and Were Initiated on TPT

[HW-11] TBI-positive: HCWs Who Were Ruled Out for TB Disease, and Are Neither PLHIV nor Eligible HH Contacts, and Tested Positive for TBI during the Reporting Period

[HW-12] TBI-positive: HCWs Who Were Ruled Out for TB Disease, Are Neither PLHIV nor Eligible Household Contacts, Tested Positive for TBI and Were Initiated on TPT

Show More Show Less

Presumptive TB (PS)

[PS-8] Number of Health Facilities Reporting on Number of Presumptive TB Patients during the Reporting Period

[PS-1] Number of Individuals Screened for TB at Healthcare Facilities

[PS-4] Number of Presumptive TB Patients Diagnosed with TB Disease

[PS-2] Number of Presumptive TB Patients Identified

[PS-5] Number of Presumptive TB Patients Who Were Ruled Out for TB Disease and Tested for TBI

[PS-3] Number of Presumptive TB Patients with Completed Evaluation for TB Disease

[PS-6] Presumptive TB Patients Tested Positive for TBI

[PS-7] Presumptive TB Patients with Chest X-ray (CXR) Performed

Show More Show Less

Prevention (PV)

[PV-2] Number of Contacts of Bacteriologically Confirmed Pulmonary TB Cases who Were Screened for TB Infection (and/or Tested for TBI) According to National Screening Protocols during the Specified Reporting Period

[PV-3] Number of Eligible (Ruled Out for TB Disease) Individuals Who Started Treatment for TB Infection during the Reporting Year

[PV-1] Number of Individuals Screened for TB Disease and TBI Outside of Health Facilities by Community Health Worker or Other Qualified Person (According to National Screening Protocols) during the Specified Reporting Period

[PV-4] Number of Individuals Who Completed Treatment for TBI during the Reporting Period

Private Sector (PR)

[PR-4] Percentage of Notified DR-TB Cases Contributed by Private Sector

[PR-2] Percentage of Notified TB Cases Contributed by Private Sector

[PR-3] Percentage of Privately Notified Pulmonary Cases with Bacteriologically Confirmed TB

[PR-5] Percentage of Privately Notified Pulmonary Cases with Confirmed Result on Rifampicin Sensitivity

[PR-7] Treatment Success Rate of DR-TB Cases Enrolled on Treatment in Private Sector

[PR-6] Treatment Success Rate of TB Cases Notified by Private Sector

Sustainability (SN)

[SN- 37A] A – Inclusiveness of NGOs in Social Contracting

[SN- 39A] A – NTP Consults with TB Civil Society/TB Survivors to Review Progress

[SN- 41A] A – NTP Staff Undertake TB and Gender Sensitization/Training

[SN-25] Annual Budget of NTP is Publicly Available

[SN-30] Anti DR-TB Drug Availability for Patients for Free

[SN-29] Anti DR-TB Drugs Listed on the Country’s National Essential Medicines List (NEML)

[SN-33] Approval Process Efficiency

[SN- 33A] Approval Process Efficiency – A

[SN- 33B] Approval Process Efficiency-B

[SN- 26B] Availability of Final JPR/JMM Report

[SN-8B] Availability of Social Health Insurance System Covering TB in the Country

[SN- 37B] B – Inclusiveness of Private Sector in Social Contracting

[SN- 41B] B – Male-Female Ratio of NTP and Provincial Managers

[SN- 39B] B – NTP Invites TB Civil Society/TB Survivors to Participate in JPR/JMM/External Reviews

[SN- 39C] C – NTP Consults with Civil Society and TB Survivors to Develop the NSP and Donor Proposals

[SN- 41C] C – TB Gender Assessment Report

[SN-6] Capacity of NTP for Absorption of Domestic Funding (In Reporting Year)

[SN-7] Capacity of NTP for Absorption of Funds from GF

[SN-22] Case Notification Data Publicly Available on NTP Website/MOH

[SN-10] Catastrophic Costs Related to TB Care

[SN- 40A] Community (Not Organized) Feedback Obtained

[SN- 39D] D – Civil Society/TB Survivors Involved in TB Research Development/Planning, Implementation, and Dissemination

[SN- 41D] D – NSP Highlights Gender Inclusiveness in TB Services and Programs

[SN-4] Domestic Funding for Drugs

[SN-5] Domestic Funding for Lab Commodities

[SN- 41E] E – Women TB Survivors Included in any NTP Event in Reporting Year

[SN-36] Effective NTP Capacity

[SN- 36C] Effective NTP Capacity in Relation to Number of Provinces

[SN- 36A] Effective NTP Capacity in Relation to Population

[SN- 36B] Effective NTP Capacity in Relation to TB Burden

[SN- 41F] F – Gender Disaggregated Data for Treatment Outcome Available for Most Recent Reported Cohort

[SN-45] First-line TB Treatment Drugs Past Expiration

[SN-39] Inclusiveness of Civil Society/TB Survivors

[SN-40] Inclusiveness of Community (Not Organized) and Subnational Entities

[SN-41] Inclusiveness of Gender

[SN-38] Inclusiveness of Key Populations (KPs)

[SN- 26A] JPR/JMM was Conducted Recently

[SN-28] Mandatory Notification

[SN-13] New WHO DR-TB Treatment Guidelines

[SN-16] Non-admission to Initiate DR-TB Treatment

[SN-35] NTP Capacity

[SN-34] NTP Manager Empowerment in the Organizational Hierarchy

[SN-21] NTP Ownership of Tools for Public Visibility

[SN-27] Partnership Statement Adoption and Implementation

[SN-14] Pediatric TB Treatment

[SN-3] Percent of TB Financing Received from Domestic Sources

[SN-9] Percent of TB Patients Covered by Insurance

[SN-20] Regimen for TBI

[SN-47] Replenishable TB Diagnostic Products Past Expiration

[SN-46] Second-line TB Treatment Drugs Past Expiration

[SN-15] Self-administered DS-TB Treatment

[SN-37] Social Contracting with Govt. Funds (NGOs/ Private Sector)

[SN-8] Social Protection

[SN-8A] Social Protection Scheme Available

[SN-17] Special Social Support for DR-TB Treatment

[SN-26] Status of TB Joint Program Review (JPR) or Joint Monitoring Mission (JMM)

[SN-42] Stockout of First-line TB Treatment Drugs

[SN-43] Stockout of Second-line TB Treatment Drugs

[SN-44] Stockout of TB Diagnostic Products

[SN-48] Stockouts of Child-friendly Formulations for TB Treatment

[SN- 40B] Subnational Government Entities Feedback Obtained

[SN-24] TB NSP Publicly Available on the NTP Website/Web Page

[SN-18] TB Screening

[SN-32] TB Stigma Reduction

[SN-23] TB Technical Guidelines Publicly Available on the NTP Website/MOH

[SN-31] TB Training Module/Guidance Contain Information on Human Rights Issues

[SN-19] TBI TPT

[SN-2] Total Funding Received for TB

[SN-12] Universal DST

[SN-11] Use of Rapid Molecular Diagnostic Testing (WHO-recommended Rapid Test) WRD

Show More Show Less

TB Detection (DT)

[DT-7] Number of Facilities Reporting Extrapulmonary TB Cases

[DT-28] Number of Laboratory-confirmed TB Cases That Are Resistant to Rifampicin and Resistant to Any Fluoroquinolone (pre-XDR-TB or XDR-TB)

[DT-5] Number of Notified Extrapulmonary TB (New and Relapse) Bacteriologically Confirmed

[DT-6] Number of Notified Extrapulmonary TB (New and Relapse) Clinically Diagnosed

[DT-4] Percent of Extrapulmonary TB Cases Notified

[DT-11] Percent of Health Facilities Implementing Intensified Case Finding (i.e., Using Standard of Practice)

[DT-26] Percent of INH Monoresistance (Previously Treated Including Relapse)

[DT-25] Percent of New TB Patients with INH Monoresistance

[DT-18] Percent of New TB Patients with Rifampicin Monoresistance

[DT-9] Percent of Prisons Conducting Regular Screening for TB According to National Policy

[DT-10] Percent of Prisons Conducting Screening for TB with Chest X-ray

[DT-34] Percent of Rapid Diagnostic Testing of New and Relapse TB Cases

[DT-20] Percent of Rifampicin Monoresistance (New and Previously Treated Including Relapse)

[DT-19] Percent of Rifampicin Monoresistance (Previously Treated Including Relapse)

[DT-8] Percent of Total Cases Notified that Were Referred or Diagnosed Via Community-based Approaches (Outside of Health Facilities) in the Basic Management Units with Data on Referrals by Community Health Workers

[DT-27] Percent of Total INH Monoresistance (New and Previously Treated Including Relapse)

[DT-13] Percent of WHO-recommended Rapid Diagnostic (WRD) Testing Sites that Are Included in a Quality Assurance Program

[DT-29] Proportion of Presumptive TB Patients Identified during the Reporting Period with Specimen Collected within Specified Target Timeframe

[DT-33] Proportion of Results Reported and Patients Initiated on Treatment during the Reporting Period within Specified Target Timeframe

[DT-30] Proportion of Specimens Collected during the Reporting Period Submitted to Testing Laboratory within Specified Target Timeframe

[DT-31] Proportion of Specimens Received at Testing Facility and Tested during the Reporting Period within Specified Target Timeframe

[DT-32] Proportion of Specimens Tested and Results Report to Referring Facility (or Physician) during the Reporting Period within Specified Target Timeframe

[DT-14] Rapid Diagnostic Testing Coverage

[DT-15] Rapid Diagnostic Testing of New and Relapse TB Cases

[DT-2] TB Case Notification Rate (CNR)

[DT-1] TB Case Notifications

[DT-21] TB Patients with Available DST Results for Isoniazid and Rifampicin

[DT-24] TB Patients with Resistance to Both Isoniazid and Rifampicin (DR-TB)

[DT-17] TB Patients with Resistance to Rifampicin (RR-TB)

[DT-16] TB Patients with Test Results for Rifampicin

[DT-22] TB Patients with Test Results for Rifampicin and Isoniazid and with Resistance to Isoniazid

[DT-23] TB Patients with Test Results for Rifampicin and Isoniazid and with Resistance to Rifampicin

Show More Show Less

TB Preventive Treatment (PT)

[PT-4] Number of Adult Household Contacts and Contacts > 5 Years Started on TPT

[PT-3] Number of Children (< 5 Years) Household Contacts Started on TPT

[PT-2] Number of Household Contacts Started on TPT

[PT-5] Number of PLHIV Started on TPT

[PT-11] Percent of Adult Household Contacts (and Contacts > 5 Years) Completed TPT

[PT-10] Percent of Children (< 5 Years) Household Contacts Completed TPT

[PT-7] Percent of Children (< 5 years) Household Contacts Started on TPT

[PT-9] Percent of Household Contacts Completed TPT

[PT-6] Percent of Household Contacts Started on TPT

[PT-12] Percent of PLHIV Completed TPT

[PT-15] Percent TPT Patients Developed TB during TPT

[PT-14] Percent TPT Patients Interrupted Due to ADR

[PT-13] Percent TPT Patients LTFU

[PT-16] Percent TPT Patients with Baseline AST/ALT Tests

Show More Show Less

TB Treatment Success (SS)

[SS-7] Percent of DS-TB patients who receive TB care package

[SS-2] TB Treatment Outcome: Died during Treatment

[SS-4] TB Treatment Outcome: LTFU

[SS-5] TB Treatment Outcome: Not Evaluated

[SS-3] TB Treatment Outcome: Treatment Failed

[SS-6] Treatment Success Rate for TB/HIV Coinfected Patients

TB/HIV (TH)

[TH-26] DR-TB/HIV Coinfected Treatment Outcome: LTFU

[TH-27] DR-TB/HIV Coinfected Treatment Outcome: Not Evaluated

[TH-25] DR-TB/HIV Coinfected Treatment Outcome: Treatment Failed

[TH-24] DR-TB/HIV Coinfection Treatment Outcome: Died during Treatment (Expressed as Percentage)

[TH-16] Percent of DR-TB Patients Recorded as HIV-positive

[TH-15] Percent of DR-TB Patients with Known HIV Status

[TH-17] Percent of DR-TB/HIV Coinfected Patients Enrolled on Appropriate DR-TB Treatment

[TH-19] Percent of HIV-positive DR-TB Patients Started or Continued on ART

[TH-18] Percent of HIV-positive TB Patients Started or Continued on ART

[TH-5] Percent of PLHIV Enrolled on ART and Tested Positive for TB Disease, Who Were Enrolled on TB Treatment

[TH-1] Percent of PLHIV Enrolled on ART Screened for TB Disease

[TH-4] Percent of PLHIV Enrolled on ART Who Tested Positive for TB Disease

[TH-6] Percent of PLHIV Enrolled on ART, Screened Negative for TB Disease

[TH-2] Percent of PLHIV Enrolled on ART, Screened Positive for TB Disease

[TH-3] Percent of PLHIV Enrolled on ART, Tested for TB Disease

[TH-7] Percent of PLHIV Enrolled on ART, Tested for TBI

[TH-8] Percent of PLHIV Enrolled on ART, Tested Positive for TBI

[TH-10] Percent of PLHIV on TPT Developed TB during TPT

[TH-11] Percent of PLHIV on TPT, and TPT Interrupted due to Adverse Drug Reaction (ADR)

[TH-12] Percent of PLHIV on TPT, with Baseline AST/ALT Tests

[TH-9] Percent of PLHIV on TPT: LTFU

[PT-8] Percent of PLHIV Started on TPT

[TH-14] Percent of TB Patients Recorded as HIV-positive

[TH-13] Percent of TB Patients with Known HIV Status

[TH-28] PLHIV with TB Who Have CD4 > 100

[TH-29] PLHIV with TB Who Have CD4 > 350

[TH-30] PLHIV with TB who have viral load testing every 6 months

[TH-20] TB/HIV Coinfected Treatment Outcome: Died during Treatment (Expressed as Percentage)

[TH-22] TB/HIV Coinfected Treatment Outcome: LTFU

[TH-23] TB/HIV Coinfected Treatment Outcome: Not Evaluated

[TH-21] TB/HIV Coinfected Treatment Outcome: Treatment Failed

Show More Show Less